Company Profile & Milestones

Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline.

  • The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.  AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties.

  • The Company’s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited and in other counties through local distributors.
    Kamada’s second leading product is KamRAB, a rabies immune globulin (Human) for Post-Exposure Prophylaxis against rabies infection. KamRAB is FDA approved and is being marketed in the U.S. under the brand name KEDRAB and through a strategic partnership with Kedrion Biopharma.

  • In addition to GLASSIA and KEDRAB, Kamada has a product line of four other plasma-derived pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia.

  • Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency, and in addition, its intravenous AAT is in development for other indications, such as GvHD, prevention of lung transplant rejection and type-1 diabetes.

  • Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 20 complementary products in Israel that are manufactured by third parties.

  • Founded in 1990, Kamada is listed on NASDAQ since 2013 and Tel-Aviv stock exchange since 2005 (KMDA).
    Kamada’s headquarters is located in the Weizmann Science Park in Rehovot, Israel.

Kamada Milestones

Kamada founded in Israel to develop and produce life-saving injectable pharmaceuticals
1991 mailstome
First product - Albumin
10 products are distributed in 15 countries
New business strategy implemented: Focus on specialty products, Strategic partnerships and cooperation, US and EU market penetration, Increasing investment in R&D
New development - liquid ready to use AAT
Orphan Drug Designation for inhaled AAT in the US and EU
Kamada becomes Israel’s first public biopharmaceutical company
First patients are treated with Kamada’s AAT IV
Strategic exclusive agreement with PARI for the eFlow device
New patents issued for AAT
Inhaled AAT: Successful completion of Phase II in CF patients, Successful completion of Phase II in Bronchiectasis patients
AAT IV - Licensure and launching in Israel, Brazil and Russia
AAT IV GLASSIA: FDA approval, Distribution and Technology license agreement with Baxalta (formerly Baxter) in US
Diabetes Type I - Phase I / II initiation
Partnership agreement with Kedrion for Rabies IG in the U.S
Initiation of snake serum production for Israel MOH
Kamada receive the Yitzhak Rabin National award for quality and excellence in the business sector
Strategic distribution agreement with Chiesi for AAT Inhaled in Europe
Successful phase I/II clinical trial results for Type-1 Diabetes
AAT Inhaled - Completion of Phase II/III
2nd extention of strategic distribusion agreement with Baxalta (formerly Baxter)
Completion of US phase III Rabies lgG clinical trial
U.S & EU orphan drug designation for AAT treat GVHD
3rd extention of strategic distribution agreement with Baxalta
Kamada’s Alpha-1 Antitrypsin Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform
FDA Approval of Expanded Label for Self-Infusion of Glassia for AAT Deficiency
Collaboration with Massachusetts General Hospital to Evaluate Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection
Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection